Applying New Evidence to Optimize Care in Advanced Prostate Cancer

Phase III COSMIC-313: addition of cabozantinib to nivolumab plus ipilimumab in previously untreated patients with IMDC intermediate- or poor-risk advanced RCC, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Phase I/II EV-103 cohort K: enfortumab vedotin with or without pembrolizumab as first-line treatment in cisplatin-ineligible locally advanced urothelial cancer, presented at ESMO and reported by Clinical Care Options (CCO)

CheckMate 274: pretreatment tumor and immune features and DFS with adjuvant nivolumab in high-risk muscle-invasive UC following radical resection, presented at ESMO 2022 and reported by Clinical Care Options (CCO)

Downloadable slides from oncology nurse experts on nursing considerations for metastatic prostate cancer, from Clinical Care Options (CCO)

Kathleen Burns, MSN, AGACNP-BC, OCN
Program Director Brenda Martone, MSN, ANP-BC, AOCNP
Program Director Released: September 22, 2022